Piroxicam | Caspian Tamin Pharmaceutical Company

stdClass Object ( [nid] => 224 [type] => product [language] => en [uid] => 1 [status] => 1 [created] => 1373586829 [changed] => 1377184464 [comment] => 0 [promote] => 0 [moderate] => 0 [sticky] => 0 [tnid] => 157 [translate] => 0 [vid] => 224 [revision_uid] => 1 [title] => Piroxicam [body] =>

The mechanism of action of piroxicam, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.

[log] => [revision_timestamp] => 1377184464 [format] => 1 [name] => root [picture] => [data] => a:5:{s:29:"taxonomy_image_disable_images";i:0;s:20:"l10n_client_disabled";i:0;s:13:"form_build_id";s:48:"form-aTcSqa5gxC3qlJ6qWYJHsxgkPEq9KwPBBC-KEX1q3PQ";s:18:"admin_compact_mode";b:1;s:7:"contact";i:0;} [path] => product/piroxicam-0 [field_one_image] => Array ( [0] => Array ( [fid] => 796 [uid] => 1 [filename] => piroxicam_s.jpg [filepath] => sites/default/files/images/piroxicam_s.jpg [filemime] => image/jpeg [filesize] => 13874 [status] => 1 [timestamp] => 1373570507 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 224 [view] => ) ) [field_administration_and_dosage] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_brand_name] => Array ( [0] => Array ( [value] => Rocamix® [format] => 1 [safe] =>

Rocamix®

[view] =>

Rocamix®

) ) [field_contraindications] => Array ( [0] => Array ( [value] => • Hypersensitivity to drug or other NSAIDs (including aspirin) • Third trimester of pregnancy [format] => 1 [safe] =>

• Hypersensitivity to drug or other NSAIDs (including aspirin)
• Third trimester of pregnancy

[view] =>

• Hypersensitivity to drug or other NSAIDs (including aspirin)
• Third trimester of pregnancy

) ) [field_dosage_form] => Array ( [0] => Array ( [value] => 0.5% Topical Gel [format] => 1 [safe] =>

0.5% Topical Gel

[view] =>

0.5% Topical Gel

) ) [field_drug_interactions] => Array ( [0] => Array ( [value] => Acetaminophen (chronic use), cyclosporine, gold compounds: increased risk of adverse renal reactions Anticoagulants, cefamandole, cefoperazone, cefotetan, clopidogrel, eptifibatide, heparin, plicamycin, thrombolytics, ticlopidine, tirofiban, valproic acid, vitamin A: increased risk of bleeding Antineoplastics: increased risk of hematologic toxicity Aspirin: decreased piroxicam blood level and efficacy Corticosteroids, other NSAIDs: additive adverse GI reactions Diuretics, other antihypertensives: decreased response to these drugs Insulin, oral hypoglycemics: increased risk of hypoglycemia Lithium: increased lithium blood level and risk of toxicity Probenecid: increased piroxicam blood level and risk of toxicity [format] => 1 [safe] =>

Acetaminophen (chronic use), cyclosporine, gold compounds: increased risk of adverse renal reactions
Anticoagulants, cefamandole, cefoperazone, cefotetan, clopidogrel, eptifibatide, heparin, plicamycin, thrombolytics, ticlopidine, tirofiban, valproic acid, vitamin A: increased risk of bleeding
Antineoplastics: increased risk of hematologic toxicity
Aspirin: decreased piroxicam blood level and efficacy
Corticosteroids, other NSAIDs: additive adverse GI reactions
Diuretics, other antihypertensives: decreased response to these drugs
Insulin, oral hypoglycemics: increased risk of hypoglycemia
Lithium: increased lithium blood level and risk of toxicity
Probenecid: increased piroxicam blood level and risk of toxicity

[view] =>

Acetaminophen (chronic use), cyclosporine, gold compounds: increased risk of adverse renal reactions
Anticoagulants, cefamandole, cefoperazone, cefotetan, clopidogrel, eptifibatide, heparin, plicamycin, thrombolytics, ticlopidine, tirofiban, valproic acid, vitamin A: increased risk of bleeding
Antineoplastics: increased risk of hematologic toxicity
Aspirin: decreased piroxicam blood level and efficacy
Corticosteroids, other NSAIDs: additive adverse GI reactions
Diuretics, other antihypertensives: decreased response to these drugs
Insulin, oral hypoglycemics: increased risk of hypoglycemia
Lithium: increased lithium blood level and risk of toxicity
Probenecid: increased piroxicam blood level and risk of toxicity

) ) [field_indications] => Array ( [0] => Array ( [value] => • osteoarthritis • rheumatoid arthritis • ankylosing spondylitis • primary dysmenorrhea [format] => 1 [safe] =>

• osteoarthritis
• rheumatoid arthritis
• ankylosing spondylitis
• primary dysmenorrhea

[view] =>

• osteoarthritis
• rheumatoid arthritis
• ankylosing spondylitis
• primary dysmenorrhea

) ) [field_packing] => Array ( [0] => Array ( [value] => Piroxicam injection 20mg /ml : 10 ampoules/box Piroxicam 0.5% topical gel : 1 tube/box- 60 g [format] => 1 [safe] =>

Piroxicam injection 20mg /ml : 10 ampoules/box
Piroxicam 0.5% topical gel : 1 tube/box- 60 g

[view] =>

Piroxicam injection 20mg /ml : 10 ampoules/box
Piroxicam 0.5% topical gel : 1 tube/box- 60 g

) ) [field_pdf] => Array ( [0] => Array ( [view] => ) ) [field_pharmacokinetics] => Array ( [0] => Array ( [value] => Distribution The apparent volume of distribution of piroxicam is approximately 0.14L/kg. Ninety-nine percent of plasma piroxicam is bound to plasma proteins. Piroxicam is excreted into human milk. The presence in breast milk has been determined during initial and long-term conditions (52 days). Piroxicam appeared in breast milk at about 1% to 3% of the maternal concentration. No accumulation of piroxicam occurred in milk relative to that in plasma during treatment. Metabolism Metabolism of piroxicam occurs by hydroxylation at the 5 position of the pyridyl side chain and conjugation of this product; by cyclodehydration; and by a sequence of reactions involving hydrolysis of the amide linkage, decarboxylation, ring contraction, and N-demethylation. The biotransformation products of piroxicam metabolism are reported to not have any anti-inflammatory activity. Excretion Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a Piroxicam dose is excreted unchanged. The plasma half-life (T½) for Piroxicam is approximately 50 hours. [format] => 1 [safe] =>

Distribution
The apparent volume of distribution of piroxicam is approximately 0.14L/kg. Ninety-nine percent of plasma piroxicam is bound to plasma proteins. Piroxicam is excreted into human milk. The presence in breast milk has been determined during initial and long-term conditions (52 days). Piroxicam appeared in breast milk at about 1% to 3% of the maternal concentration. No accumulation of piroxicam occurred in milk relative to that in plasma during treatment.
Metabolism
Metabolism of piroxicam occurs by hydroxylation at the 5 position of the pyridyl side chain and conjugation of this product; by cyclodehydration; and by a sequence of reactions involving hydrolysis of the amide linkage, decarboxylation, ring contraction, and N-demethylation. The biotransformation products of piroxicam metabolism are reported to not have any anti-inflammatory activity.
Excretion
Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a Piroxicam dose is excreted unchanged. The plasma half-life (T½) for Piroxicam is approximately 50 hours.

[view] =>

Distribution
The apparent volume of distribution of piroxicam is approximately 0.14L/kg. Ninety-nine percent of plasma piroxicam is bound to plasma proteins. Piroxicam is excreted into human milk. The presence in breast milk has been determined during initial and long-term conditions (52 days). Piroxicam appeared in breast milk at about 1% to 3% of the maternal concentration. No accumulation of piroxicam occurred in milk relative to that in plasma during treatment.
Metabolism
Metabolism of piroxicam occurs by hydroxylation at the 5 position of the pyridyl side chain and conjugation of this product; by cyclodehydration; and by a sequence of reactions involving hydrolysis of the amide linkage, decarboxylation, ring contraction, and N-demethylation. The biotransformation products of piroxicam metabolism are reported to not have any anti-inflammatory activity.
Excretion
Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a Piroxicam dose is excreted unchanged. The plasma half-life (T½) for Piroxicam is approximately 50 hours.

) ) [field_pharmacological_category] => Array ( [0] => Array ( [value] => Non-steroidal anti-inflammatory drug (NSAID) [format] => 1 [safe] =>

Non-steroidal anti-inflammatory drug (NSAID)

[view] =>

Non-steroidal anti-inflammatory drug (NSAID)

) ) [field_precautions] => Array ( [0] => Array ( [value] => • renal impairment, severe cardiovascular or hepatic disease • pregnant patients in first or secondtrimester • breastfeeding patients (not recommended) • children (safety not established). [format] => 1 [safe] =>

• renal impairment, severe cardiovascular or hepatic disease
• pregnant patients in first or secondtrimester
• breastfeeding patients (not recommended)
• children (safety not established).

[view] =>

• renal impairment, severe cardiovascular or hepatic disease
• pregnant patients in first or secondtrimester
• breastfeeding patients (not recommended)
• children (safety not established).

) ) [field_pregnancy_category] => Array ( [0] => Array ( [value] => category C [format] => 1 [safe] =>

category C

[view] =>

category C

) ) [field_references] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_side_effects] => Array ( [0] => Array ( [value] => CNS: headache, drowsiness, dizziness CV: edema, hypertension, vasculitis, tachycardia, arrhythmias EENT: blurred vision, tinnitus GU: proteinuria, renal failure Hematologic: anemia, blood dyscrasias Hepatic: jaundice, hepatitis Skin: rash Other: allergic reactions including anaphylaxis [format] => 1 [safe] =>

CNS: headache, drowsiness, dizziness
CV: edema, hypertension, vasculitis, tachycardia, arrhythmias
EENT: blurred vision, tinnitus
GU: proteinuria, renal failure
Hematologic: anemia, blood dyscrasias
Hepatic: jaundice, hepatitis
Skin: rash
Other: allergic reactions including anaphylaxis

[view] =>

CNS: headache, drowsiness, dizziness
CV: edema, hypertension, vasculitis, tachycardia, arrhythmias
EENT: blurred vision, tinnitus
GU: proteinuria, renal failure
Hematologic: anemia, blood dyscrasias
Hepatic: jaundice, hepatitis
Skin: rash
Other: allergic reactions including anaphylaxis

) ) [field_storage] => Array ( [0] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[view] =>

• Store below 30 C°
• Protect from light and freezing

) ) [field_therapeutic_category] => Array ( [0] => Array ( [value] => Analgesic, anti-inflammatory, antipyretic [format] => 1 [safe] =>

Analgesic, anti-inflammatory, antipyretic

[view] =>

Analgesic, anti-inflammatory, antipyretic

) ) [field_related_products] => Array ( [0] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [1] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [2] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) ) [taxonomy] => Array ( [21] => stdClass Object ( [tid] => 21 [vid] => 1 [name] => Anlagesics Anti-inflammatory Drugs [description] => [weight] => 0 [language] => [trid] => 0 [v_weight_unused] => 0 ) ) [build_mode] => 0 [readmore] => [content] => Array ( [field_one_image] => Array ( [#type_name] => product [#context] => full [#field_name] => field_one_image [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -3 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => image_plain [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_one_image [#weight] => 0 [#theme] => imagefield_formatter_image_plain [#item] => Array ( [fid] => 796 [uid] => 1 [filename] => piroxicam_s.jpg [filepath] => sites/default/files/images/piroxicam_s.jpg [filemime] => image/jpeg [filesize] => 13874 [status] => 1 [timestamp] => 1373570507 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 224 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_one_image [#title] => Image [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_brand_name] => Array ( [#type_name] => product [#context] => full [#field_name] => field_brand_name [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_brand_name [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Rocamix® [format] => 1 [safe] =>

Rocamix®

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Rocamix®

) [#title] => [#description] => [#children] =>

Rocamix®

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_brand_name [#title] => Brand Name [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Rocamix®

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_dosage_form] => Array ( [#type_name] => product [#context] => full [#field_name] => field_dosage_form [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_dosage_form [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => 0.5% Topical Gel [format] => 1 [safe] =>

0.5% Topical Gel

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

0.5% Topical Gel

) [#title] => [#description] => [#children] =>

0.5% Topical Gel

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_dosage_form [#title] => Dosage Form [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

0.5% Topical Gel

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#pre_render] => Array ( [0] => content_alter_extra_weights ) [field_pharmacological_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacological_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 0 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacological_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Non-steroidal anti-inflammatory drug (NSAID) [format] => 1 [safe] =>

Non-steroidal anti-inflammatory drug (NSAID)

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Non-steroidal anti-inflammatory drug (NSAID)

) [#title] => [#description] => [#children] =>

Non-steroidal anti-inflammatory drug (NSAID)

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacological_category [#title] => Pharmacological Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Non-steroidal anti-inflammatory drug (NSAID)

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#content_extra_fields] => Array ( [title] => Array ( [label] => Generic Name [description] => Node module form. [weight] => -5 ) [body_field] => Array ( [label] => Pharmacology [description] => Node module form. [weight] => 3 [view] => body ) [revision_information] => Array ( [label] => Revision information [description] => Node module form. [weight] => 18 ) [author] => Array ( [label] => Authoring information [description] => Node module form. [weight] => 19 ) [options] => Array ( [label] => Publishing options [description] => Node module form. [weight] => 20 ) [language] => Array ( [label] => Language [description] => Locale module form. [weight] => -4 ) [translation] => Array ( [label] => Translation settings [description] => Translation module form. [weight] => 21 ) [menu] => Array ( [label] => Menu settings [description] => Menu module form. [weight] => 17 ) [taxonomy] => Array ( [label] => Taxonomy [description] => Taxonomy module form. [weight] => -3 ) [path] => Array ( [label] => Path settings [description] => Path module form. [weight] => 16 ) [custom_breadcrumbs] => Array ( [label] => Custom Breadcrumbs [description] => Custom Breadcrumbs module form. [weight] => 30 ) ) [field_therapeutic_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_therapeutic_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 1 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_therapeutic_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Analgesic, anti-inflammatory, antipyretic [format] => 1 [safe] =>

Analgesic, anti-inflammatory, antipyretic

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Analgesic, anti-inflammatory, antipyretic

) [#title] => [#description] => [#children] =>

Analgesic, anti-inflammatory, antipyretic

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_therapeutic_category [#title] => Therapeutic Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Analgesic, anti-inflammatory, antipyretic

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_pregnancy_category] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pregnancy_category [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 2 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pregnancy_category [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => category C [format] => 1 [safe] =>

category C

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

category C

) [#title] => [#description] => [#children] =>

category C

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pregnancy_category [#title] => Pregnancy Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

category C

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [body] => Array ( [#weight] => 3 [#value] =>

The mechanism of action of piroxicam, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.

[#title] => [#description] => [#printed] => 1 ) [field_pharmacokinetics] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacokinetics [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 4 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacokinetics [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Distribution The apparent volume of distribution of piroxicam is approximately 0.14L/kg. Ninety-nine percent of plasma piroxicam is bound to plasma proteins. Piroxicam is excreted into human milk. The presence in breast milk has been determined during initial and long-term conditions (52 days). Piroxicam appeared in breast milk at about 1% to 3% of the maternal concentration. No accumulation of piroxicam occurred in milk relative to that in plasma during treatment. Metabolism Metabolism of piroxicam occurs by hydroxylation at the 5 position of the pyridyl side chain and conjugation of this product; by cyclodehydration; and by a sequence of reactions involving hydrolysis of the amide linkage, decarboxylation, ring contraction, and N-demethylation. The biotransformation products of piroxicam metabolism are reported to not have any anti-inflammatory activity. Excretion Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a Piroxicam dose is excreted unchanged. The plasma half-life (T½) for Piroxicam is approximately 50 hours. [format] => 1 [safe] =>

Distribution
The apparent volume of distribution of piroxicam is approximately 0.14L/kg. Ninety-nine percent of plasma piroxicam is bound to plasma proteins. Piroxicam is excreted into human milk. The presence in breast milk has been determined during initial and long-term conditions (52 days). Piroxicam appeared in breast milk at about 1% to 3% of the maternal concentration. No accumulation of piroxicam occurred in milk relative to that in plasma during treatment.
Metabolism
Metabolism of piroxicam occurs by hydroxylation at the 5 position of the pyridyl side chain and conjugation of this product; by cyclodehydration; and by a sequence of reactions involving hydrolysis of the amide linkage, decarboxylation, ring contraction, and N-demethylation. The biotransformation products of piroxicam metabolism are reported to not have any anti-inflammatory activity.
Excretion
Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a Piroxicam dose is excreted unchanged. The plasma half-life (T½) for Piroxicam is approximately 50 hours.

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Distribution
The apparent volume of distribution of piroxicam is approximately 0.14L/kg. Ninety-nine percent of plasma piroxicam is bound to plasma proteins. Piroxicam is excreted into human milk. The presence in breast milk has been determined during initial and long-term conditions (52 days). Piroxicam appeared in breast milk at about 1% to 3% of the maternal concentration. No accumulation of piroxicam occurred in milk relative to that in plasma during treatment.
Metabolism
Metabolism of piroxicam occurs by hydroxylation at the 5 position of the pyridyl side chain and conjugation of this product; by cyclodehydration; and by a sequence of reactions involving hydrolysis of the amide linkage, decarboxylation, ring contraction, and N-demethylation. The biotransformation products of piroxicam metabolism are reported to not have any anti-inflammatory activity.
Excretion
Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a Piroxicam dose is excreted unchanged. The plasma half-life (T½) for Piroxicam is approximately 50 hours.

) [#title] => [#description] => [#children] =>

Distribution
The apparent volume of distribution of piroxicam is approximately 0.14L/kg. Ninety-nine percent of plasma piroxicam is bound to plasma proteins. Piroxicam is excreted into human milk. The presence in breast milk has been determined during initial and long-term conditions (52 days). Piroxicam appeared in breast milk at about 1% to 3% of the maternal concentration. No accumulation of piroxicam occurred in milk relative to that in plasma during treatment.
Metabolism
Metabolism of piroxicam occurs by hydroxylation at the 5 position of the pyridyl side chain and conjugation of this product; by cyclodehydration; and by a sequence of reactions involving hydrolysis of the amide linkage, decarboxylation, ring contraction, and N-demethylation. The biotransformation products of piroxicam metabolism are reported to not have any anti-inflammatory activity.
Excretion
Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a Piroxicam dose is excreted unchanged. The plasma half-life (T½) for Piroxicam is approximately 50 hours.

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacokinetics [#title] => Pharmacokinetics [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Distribution
The apparent volume of distribution of piroxicam is approximately 0.14L/kg. Ninety-nine percent of plasma piroxicam is bound to plasma proteins. Piroxicam is excreted into human milk. The presence in breast milk has been determined during initial and long-term conditions (52 days). Piroxicam appeared in breast milk at about 1% to 3% of the maternal concentration. No accumulation of piroxicam occurred in milk relative to that in plasma during treatment.
Metabolism
Metabolism of piroxicam occurs by hydroxylation at the 5 position of the pyridyl side chain and conjugation of this product; by cyclodehydration; and by a sequence of reactions involving hydrolysis of the amide linkage, decarboxylation, ring contraction, and N-demethylation. The biotransformation products of piroxicam metabolism are reported to not have any anti-inflammatory activity.
Excretion
Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a Piroxicam dose is excreted unchanged. The plasma half-life (T½) for Piroxicam is approximately 50 hours.

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_indications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_indications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 5 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_indications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • osteoarthritis • rheumatoid arthritis • ankylosing spondylitis • primary dysmenorrhea [format] => 1 [safe] =>

• osteoarthritis
• rheumatoid arthritis
• ankylosing spondylitis
• primary dysmenorrhea

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• osteoarthritis
• rheumatoid arthritis
• ankylosing spondylitis
• primary dysmenorrhea

) [#title] => [#description] => [#children] =>

• osteoarthritis
• rheumatoid arthritis
• ankylosing spondylitis
• primary dysmenorrhea

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_indications [#title] => Indications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• osteoarthritis
• rheumatoid arthritis
• ankylosing spondylitis
• primary dysmenorrhea

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_administration_and_dosage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_administration_and_dosage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 6 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_administration_and_dosage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_administration_and_dosage [#title] => Administration and Dosage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_contraindications] => Array ( [#type_name] => product [#context] => full [#field_name] => field_contraindications [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 7 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_contraindications [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Hypersensitivity to drug or other NSAIDs (including aspirin) • Third trimester of pregnancy [format] => 1 [safe] =>

• Hypersensitivity to drug or other NSAIDs (including aspirin)
• Third trimester of pregnancy

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Hypersensitivity to drug or other NSAIDs (including aspirin)
• Third trimester of pregnancy

) [#title] => [#description] => [#children] =>

• Hypersensitivity to drug or other NSAIDs (including aspirin)
• Third trimester of pregnancy

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_contraindications [#title] => Contraindications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Hypersensitivity to drug or other NSAIDs (including aspirin)
• Third trimester of pregnancy

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_precautions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_precautions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 8 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_precautions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • renal impairment, severe cardiovascular or hepatic disease • pregnant patients in first or secondtrimester • breastfeeding patients (not recommended) • children (safety not established). [format] => 1 [safe] =>

• renal impairment, severe cardiovascular or hepatic disease
• pregnant patients in first or secondtrimester
• breastfeeding patients (not recommended)
• children (safety not established).

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• renal impairment, severe cardiovascular or hepatic disease
• pregnant patients in first or secondtrimester
• breastfeeding patients (not recommended)
• children (safety not established).

) [#title] => [#description] => [#children] =>

• renal impairment, severe cardiovascular or hepatic disease
• pregnant patients in first or secondtrimester
• breastfeeding patients (not recommended)
• children (safety not established).

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_precautions [#title] => Precautions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• renal impairment, severe cardiovascular or hepatic disease
• pregnant patients in first or secondtrimester
• breastfeeding patients (not recommended)
• children (safety not established).

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_drug_interactions] => Array ( [#type_name] => product [#context] => full [#field_name] => field_drug_interactions [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 9 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_drug_interactions [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Acetaminophen (chronic use), cyclosporine, gold compounds: increased risk of adverse renal reactions Anticoagulants, cefamandole, cefoperazone, cefotetan, clopidogrel, eptifibatide, heparin, plicamycin, thrombolytics, ticlopidine, tirofiban, valproic acid, vitamin A: increased risk of bleeding Antineoplastics: increased risk of hematologic toxicity Aspirin: decreased piroxicam blood level and efficacy Corticosteroids, other NSAIDs: additive adverse GI reactions Diuretics, other antihypertensives: decreased response to these drugs Insulin, oral hypoglycemics: increased risk of hypoglycemia Lithium: increased lithium blood level and risk of toxicity Probenecid: increased piroxicam blood level and risk of toxicity [format] => 1 [safe] =>

Acetaminophen (chronic use), cyclosporine, gold compounds: increased risk of adverse renal reactions
Anticoagulants, cefamandole, cefoperazone, cefotetan, clopidogrel, eptifibatide, heparin, plicamycin, thrombolytics, ticlopidine, tirofiban, valproic acid, vitamin A: increased risk of bleeding
Antineoplastics: increased risk of hematologic toxicity
Aspirin: decreased piroxicam blood level and efficacy
Corticosteroids, other NSAIDs: additive adverse GI reactions
Diuretics, other antihypertensives: decreased response to these drugs
Insulin, oral hypoglycemics: increased risk of hypoglycemia
Lithium: increased lithium blood level and risk of toxicity
Probenecid: increased piroxicam blood level and risk of toxicity

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Acetaminophen (chronic use), cyclosporine, gold compounds: increased risk of adverse renal reactions
Anticoagulants, cefamandole, cefoperazone, cefotetan, clopidogrel, eptifibatide, heparin, plicamycin, thrombolytics, ticlopidine, tirofiban, valproic acid, vitamin A: increased risk of bleeding
Antineoplastics: increased risk of hematologic toxicity
Aspirin: decreased piroxicam blood level and efficacy
Corticosteroids, other NSAIDs: additive adverse GI reactions
Diuretics, other antihypertensives: decreased response to these drugs
Insulin, oral hypoglycemics: increased risk of hypoglycemia
Lithium: increased lithium blood level and risk of toxicity
Probenecid: increased piroxicam blood level and risk of toxicity

) [#title] => [#description] => [#children] =>

Acetaminophen (chronic use), cyclosporine, gold compounds: increased risk of adverse renal reactions
Anticoagulants, cefamandole, cefoperazone, cefotetan, clopidogrel, eptifibatide, heparin, plicamycin, thrombolytics, ticlopidine, tirofiban, valproic acid, vitamin A: increased risk of bleeding
Antineoplastics: increased risk of hematologic toxicity
Aspirin: decreased piroxicam blood level and efficacy
Corticosteroids, other NSAIDs: additive adverse GI reactions
Diuretics, other antihypertensives: decreased response to these drugs
Insulin, oral hypoglycemics: increased risk of hypoglycemia
Lithium: increased lithium blood level and risk of toxicity
Probenecid: increased piroxicam blood level and risk of toxicity

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_drug_interactions [#title] => Drug Interactions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Acetaminophen (chronic use), cyclosporine, gold compounds: increased risk of adverse renal reactions
Anticoagulants, cefamandole, cefoperazone, cefotetan, clopidogrel, eptifibatide, heparin, plicamycin, thrombolytics, ticlopidine, tirofiban, valproic acid, vitamin A: increased risk of bleeding
Antineoplastics: increased risk of hematologic toxicity
Aspirin: decreased piroxicam blood level and efficacy
Corticosteroids, other NSAIDs: additive adverse GI reactions
Diuretics, other antihypertensives: decreased response to these drugs
Insulin, oral hypoglycemics: increased risk of hypoglycemia
Lithium: increased lithium blood level and risk of toxicity
Probenecid: increased piroxicam blood level and risk of toxicity

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_side_effects] => Array ( [#type_name] => product [#context] => full [#field_name] => field_side_effects [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 10 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_side_effects [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => CNS: headache, drowsiness, dizziness CV: edema, hypertension, vasculitis, tachycardia, arrhythmias EENT: blurred vision, tinnitus GU: proteinuria, renal failure Hematologic: anemia, blood dyscrasias Hepatic: jaundice, hepatitis Skin: rash Other: allergic reactions including anaphylaxis [format] => 1 [safe] =>

CNS: headache, drowsiness, dizziness
CV: edema, hypertension, vasculitis, tachycardia, arrhythmias
EENT: blurred vision, tinnitus
GU: proteinuria, renal failure
Hematologic: anemia, blood dyscrasias
Hepatic: jaundice, hepatitis
Skin: rash
Other: allergic reactions including anaphylaxis

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

CNS: headache, drowsiness, dizziness
CV: edema, hypertension, vasculitis, tachycardia, arrhythmias
EENT: blurred vision, tinnitus
GU: proteinuria, renal failure
Hematologic: anemia, blood dyscrasias
Hepatic: jaundice, hepatitis
Skin: rash
Other: allergic reactions including anaphylaxis

) [#title] => [#description] => [#children] =>

CNS: headache, drowsiness, dizziness
CV: edema, hypertension, vasculitis, tachycardia, arrhythmias
EENT: blurred vision, tinnitus
GU: proteinuria, renal failure
Hematologic: anemia, blood dyscrasias
Hepatic: jaundice, hepatitis
Skin: rash
Other: allergic reactions including anaphylaxis

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_side_effects [#title] => Side Effects [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

CNS: headache, drowsiness, dizziness
CV: edema, hypertension, vasculitis, tachycardia, arrhythmias
EENT: blurred vision, tinnitus
GU: proteinuria, renal failure
Hematologic: anemia, blood dyscrasias
Hepatic: jaundice, hepatitis
Skin: rash
Other: allergic reactions including anaphylaxis

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_storage] => Array ( [#type_name] => product [#context] => full [#field_name] => field_storage [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 11 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_storage [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => • Store below 30 C° • Protect from light and freezing [format] => 1 [safe] =>

• Store below 30 C°
• Protect from light and freezing

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

) [#title] => [#description] => [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_storage [#title] => Storage [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

• Store below 30 C°
• Protect from light and freezing

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_packing] => Array ( [#type_name] => product [#context] => full [#field_name] => field_packing [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 12 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_packing [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Piroxicam injection 20mg /ml : 10 ampoules/box Piroxicam 0.5% topical gel : 1 tube/box- 60 g [format] => 1 [safe] =>

Piroxicam injection 20mg /ml : 10 ampoules/box
Piroxicam 0.5% topical gel : 1 tube/box- 60 g

[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>

Piroxicam injection 20mg /ml : 10 ampoules/box
Piroxicam 0.5% topical gel : 1 tube/box- 60 g

) [#title] => [#description] => [#children] =>

Piroxicam injection 20mg /ml : 10 ampoules/box
Piroxicam 0.5% topical gel : 1 tube/box- 60 g

[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_packing [#title] => Packing [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>

Piroxicam injection 20mg /ml : 10 ampoules/box
Piroxicam 0.5% topical gel : 1 tube/box- 60 g

[#printed] => 1 ) [#title] => [#description] => [#children] => [#printed] => 1 ) [field_references] => Array ( [#type_name] => product [#context] => full [#field_name] => field_references [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 13 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_references [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => [format] => [safe] => [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_references [#title] => References [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_pdf] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pdf [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 14 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pdf [#weight] => 0 [#theme] => filefield_formatter_default [#item] => Array ( [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pdf [#title] => PDF [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [field_related_products] => Array ( [#type_name] => product [#context] => full [#field_name] => field_related_products [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 15 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 0 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [1] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 1 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 1 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [2] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_related_products [#weight] => 2 [#theme] => nodereference_formatter_default [#item] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [#delta] => 2 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => ) [#title] => [#description] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_related_products [#title] => Related Products [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#printed] => 1 ) [#title] => [#description] => [#printed] => 1 ) [#title] => [#description] => [#children] =>

The mechanism of action of piroxicam, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.

[#printed] => 1 ) [links] => Array ( [node_translation_fa] => Array ( [title] => فارسی [href] => node/157 [language] => stdClass Object ( [language] => fa [name] => Persian [native] => فارسی [direction] => 1 [enabled] => 1 [plurals] => 0 [formula] => [domain] => [prefix] => fa [weight] => 3 [javascript] => ) [attributes] => Array ( [title] => پیروکسیکام [class] => translation-link ) ) ) )